First-line for neuropathic pain per NeuPSIG 2015 and IASP 2022. Used in diabetic polyneuropathy, post-herpetic neuralgia, and spinal pain. Start 75 mg twice daily; titrate to 150–300 mg twice daily. Max 600 mg/day. Onset over 1–2 weeks. Pregabalin carries a potential for misuse and dependence with a withdrawal syndrome; it is a controlled substance in several countries (UK Class C since 2019), so taper the dose gradually.
Pregabalin is -approved for fibromyalgia (one of three drugs with this indication, alongside duloxetine and milnacipran); in the EU the indication is not registered (the application failed), so in Spain it is off-label. Per 2017, the only strong-for recommendation in fibromyalgia is exercise; all pharmacotherapy, pregabalin included, is a weak-for adjunct for a specific profile (pain, sleep disturbance). The pain effect is modest (NNT about 8), with a more noticeable effect on sleep. Dose 150–450 mg/day. Risks: dependence and abuse, weight gain, dizziness.
In Europe, pregabalin is -approved for generalized anxiety disorder; not in the US. Per NG113, second-line after SSRI/SNRI failure. Dose 150–600 mg/day. Efficacy comparable to SSRIs with faster onset (1–2 weeks vs 4–6). Advantage: no sexual dysfunction. Disadvantage: dependence/abuse risk, weight gain.
The drug is promoted for these uses outside international guidelines. Each entry below is analyzed against AEMPS, FDA, EMA, Cochrane and major RCTs.
F
Stress and anxiety
Not recommended
+
Pregabalin (Lyrica) is an antiepileptic drug prescribed for neuropathic pain, fibromyalgia, generalized anxiety disorder, and partial epilepsy. For stress, insomnia, or emotional tension outside these indications, pregabalin is dangerous. The drug is a controlled substance in the US (Schedule V), the UK (Schedule 3 since 2019), and Russia (prescription-only with special requirements since 2019) because of abuse and dependence potential. In patients with a history of substance use disorder, the risk of pregabalin dependence is significant. On black markets in Eastern Europe and the CIS, Lyrica is one of the most popular illicit drugs. Abrupt discontinuation causes a severe withdrawal syndrome: anxiety, insomnia, tachycardia, and sometimes seizures. If pregabalin was prescribed for stress or sleep, consider seeking a second opinion.
AStrong evidence – first or second line in international guidelines
BRecommended in selected cases
CStudy data contradict each other
DBenefit not proven, no documented harm
FDocumented harm, or risk without benefit
Mechanism of action
GABA analogue that, like gabapentin, binds the α2δ subunit of voltage-gated calcium channels in the CNS. Inhibits excitatory neurotransmitter release. Compared with gabapentin, pharmacokinetics are more linear — bioavailability 90 % regardless of dose, simplifying titration. Effects on neuropathic pain and anxiety are comparable to gabapentin at much lower doses. Controlled substance: Schedule V in the US (since 2005) and Schedule 3 in the UK (since 2019).
Safety
Contraindications
Hypersensitivity
Age under 18 (for most indications except pediatric epilepsy from age 4)
Rare hereditary galactose intolerance
Serious adverse effects
Respiratory depression with opioids or other CNS depressants
Pregabalin dependence and withdrawal on discontinuation
AEMPS summary of product characteristics (section 4.6): animal studies have shown reproductive toxicity; pregabalin crosses the placenta in rats and may cross the human placenta. In a Nordic observational study of more than 2,700 women exposed in the first trimester, major congenital malformations were more common than in unexposed pregnancies (5.9% versus 4.1%; adjusted prevalence ratio 1.14, 95% CI 0.96 to 1.35) and than after exposure to lamotrigine (1.29) or duloxetine (1.39). Analyses of specific malformations showed a higher risk of nervous system, eye, orofacial cleft, urinary and genital malformations, but numbers were small and the estimates imprecise. Pregabalin should not be used in pregnancy unless clearly necessary, that is, when the benefit to the mother clearly outweighs the potential risk to the fetus.
Breastfeeding: can you take Pregabalin?
Transfers into breast milk. Manufacturer label advises against breastfeeding. Per LactMed, use when necessary with infant monitoring for sedation and poor weight gain.
Reference information, not a clinical decision. Discuss feeding pauses or changes with your physician or an IBCLC.
Practical notes
Timing and administration
Take twice daily with or without food, at the same times. Start 75 mg twice daily; increase to 150 mg twice daily after 3–7 days. Lower doses in elderly and eGFR below 60. Tapering: reduce by 25–50 % every 4–7 days over at least 1 week — abrupt discontinuation causes withdrawal.
Special situations
Combined with opioids, the risk of respiratory depression and mortality rises — added a 2019 warning. In patients with prior or current substance use disorder, pregabalin dependence risk is significant — evaluate indication and alternatives. In depressed patients, suicidal ideation may occur in early weeks — close monitoring.
Common myths
Myth: 'Lyrica is a harmless anti-stress drug'. Fact: pregabalin is a controlled substance with dependence and abuse risk. Use without a clinical diagnosis is unsafe.
Myth: 'Lyrica helps me sleep'. Fact: pregabalin causes sedation, but as a side effect — not as an indication. For insomnia, drugs with better safety profiles exist (melatonin, short-course doxylamine, third-generation hypnotics on indication). Self-medicating insomnia with pregabalin is unjustified.
Alprazolam and pregabalin depress the central nervous system (CNS) by different pathways, and their effects add up. The alprazolam SmPC warns that combining it with antiepileptics increases CNS depression and the risk of respiratory depression, coma and death (alprazolam SmPC). Pregabalin enhances the effect of lorazepam, another benzodiazepine, and post-marketing reports describe respiratory failure, coma and death when pregabalin was taken with CNS depressants (pregabalin SmPC of the European Medicines Agency, ).
Symptoms
Drowsiness, dizziness, slowed thinking, impaired coordination. With marked depression: slow, shallow breathing, confusion and loss of consciousness (alprazolam and pregabalin SmPCs). In older patients, drowsiness and dizziness increase the risk of falls (alprazolam and pregabalin SmPCs).
Management
The alprazolam SmPC requires limiting the dose and duration of co-administration with antiepileptics, which include pregabalin (alprazolam SmPC; alprazolam label of the US Food and Drug Administration, ). Use alprazolam at the lowest effective dose for the shortest time, no longer than 2–4 weeks; in older patients, start with 0.25 mg two or three times a day and use caution because of sedation, muscle weakness and the risk of falls (alprazolam SmPC). The risk of severe respiratory depression is higher when pregabalin is taken with central nervous system depressants, in older patients and in those with lung disease, neurological disease or renal impairment; these patients may need a pregabalin dose adjustment (pregabalin SmPC of the European Medicines Agency, ). Advise the patient not to drive or operate machinery while taking alprazolam (alprazolam FDA label).
Pregabalin acts via the α2δ subunit of calcium channels and depresses the central nervous system. Morphine suppresses the respiratory centre via μ-opioid receptors. Effects are additive.
Symptoms
Drowsiness, slowed breathing (rate below 12/min), cyanosis of lips. Severe cases include respiratory arrest. Older patients: fall risk.
Management
The combination is possible in neuropathic pain or palliative cancer pain with careful titration. Keep doses minimal, provide naloxone to the patient and family, monitor respiratory rate and saturation.
Pregabalin and oxycodone depress the central nervous system (CNS) through different pathways, and their effects add up. Oxycodone, like all opioids, blunts the respiratory centre. Pregabalin on its own causes somnolence, dizziness and, rarely, severe respiratory depression, and the risk rises with other CNS depressants (pregabalin SmPC, , section 4.4). There is no pharmacokinetic interaction. Pregabalin is barely metabolised and leaves the body unchanged in urine, and in a study with oxycodone the levels of both drugs stayed the same (pregabalin SmPC, EMA, section 4.5; label of pregabalin, section 7). Pregabalin does, however, add to the cognitive and motor impairment that oxycodone causes (pregabalin SmPC, EMA, section 4.5). Both drugs slow the gut: constipation, paralytic ileus and intestinal obstruction have been reported with the combination (pregabalin SmPC, EMA, section 4.4).
Symptoms
Somnolence, slowed thinking, dizziness, poor coordination and falls, especially in older patients. In severe cases, slow shallow breathing, deep sedation, coma and death: such cases were reported after marketing in patients taking pregabalin with opioids and other CNS depressants (pregabalin SmPC, , section 4.5; oxycodone SmPC, AEMPS, section 4.5). In an observational study, patients taking pregabalin with an opioid had a 1.68-fold higher risk of opioid-related death than those on an opioid alone. The rise was already present at pregabalin doses of 300 mg per day or less (pregabalin SmPC, EMA, section 4.4). The risk is highest at the start of treatment and after a dose increase, and in patients with impaired breathing, renal failure or older age (pregabalin SmPC, EMA, section 4.4; label of oxycodone, section 5.2). Constipation up to intestinal obstruction is a separate concern.
Management
The combination is allowed, but under strict limits. The oxycodone SmPC names pregabalin among CNS depressants. It requires limiting the dose and duration of concomitant use and reserving such pairs for patients with no alternative treatment options (oxycodone SmPC, AEMPS, sections 4.4 and 4.5; label of oxycodone, sections 5.3 and 7). Use the lowest effective dose and the shortest possible course (oxycodone SmPC, AEMPS, section 4.4). When starting oxycodone in a patient already on pregabalin, begin with one-third to one-half of the usual starting dose of oxycodone and consider a lower pregabalin dose (FDA label of oxycodone, section 2.6). When adding pregabalin to an opioid, start it at a low dose (FDA label of pregabalin, section 5.5) and adjust it to renal function, because renal impairment, lung disease and older age raise the risk of respiratory depression (pregabalin SmPC, , sections 4.2 and 4.4). Warn the patient and carers about the signs of respiratory depression and sedation and watch for them, especially in the first days and after every dose increase (oxycodone SmPC, AEMPS, section 4.4; pregabalin SmPC, EMA, section 4.4). The FDA advises considering an opioid overdose reversal agent, naloxone or nalmefene, for this combination (FDA label of oxycodone, section 5.3). If respiratory depression appears, reduce or withdraw the CNS depressants, including pregabalin (FDA label of pregabalin, section 5.5). Consider measures against constipation, especially in women and older patients (pregabalin SmPC, EMA, section 4.4).
Similar to tramadol + gabapentin: additive CNS depression, seizure risk (tramadol lowers threshold). issued a 2019 warning about respiratory depression with opioid-gabapentinoid combinations.
Symptoms
Drowsiness, sedation, slowed breathing. Seizures (tramadol) and syncope from orthostatic hypotension are possible. Older patients: fall risk.
Management
The combination is possible in neuropathic pain. Keep doses minimal, start low. Warn the patient about drowsiness and ataxia. Older patients: enhanced fall monitoring. Alternative opioid for neuropathic pain: pure opioid agonist (morphine, oxycodone) without serotonergic activity.
Similar to amitriptyline plus gabapentin — additive CNS depression. The combination is widely used in neuropathic pain, especially when monotherapy is insufficient.
Symptoms
Sedation, fatigue, slowed reactions, impaired coordination. In older patients: fall and fracture risk. Driving and operating machinery: accident risk.
Management
For neuropathic pain, start both at minimum doses: amitriptyline 10 mg at bedtime, pregabalin 75 mg twice daily. Up-titrate every 1–2 weeks as tolerated. Avoid in older patients — fall risk. Alternatives: duloxetine with topicals.
Verbatim lines from the interaction sections, in the language of the label
From this drug’s label
Moderateopioidesclass named in the label
«Disminución de la funcionalidad del tracto gastrointestinal inferior: Durante el periodo post-comercialización se han notificado casos relacionados con la disminución de la funcionalidad del tracto…»
«Estudios in vivo y análisis farmacocinético de la población: En consecuencia, en los estudios in vivo , no se observaron interacciones farmacocinéticas relevantes desde el punto de vista clínico…»
«DRUG INTERACTIONS: Multiple oral doses of pregabalin were co-administered with oxycodone, lorazepam, or ethanol. Although no pharmacokinetic interactions were seen, additive effects on cognitive and…»
«Estudios in vivo y análisis farmacocinético de la población: En consecuencia, en los estudios in vivo , no se observaron interacciones farmacocinéticas relevantes desde el punto de vista clínico…»
«Estudios in vivo y análisis farmacocinético de la población: En consecuencia, en los estudios in vivo , no se observaron interacciones farmacocinéticas relevantes desde el punto de vista clínico…»
«Estudios in vivo y análisis farmacocinético de la población: En consecuencia, en los estudios in vivo , no se observaron interacciones farmacocinéticas relevantes desde el punto de vista clínico…»
«DRUG INTERACTIONS: Since pregabalin is predominantly excreted unchanged in the urine, undergoes negligible metabolism in humans (less than 2% of a dose recovered in urine as metabolites), and does…»
«Estudios in vivo y análisis farmacocinético de la población: En consecuencia, en los estudios in vivo , no se observaron interacciones farmacocinéticas relevantes desde el punto de vista clínico…»
«DRUG INTERACTIONS: Multiple oral doses of pregabalin were co-administered with oxycodone, lorazepam, or ethanol. Although no pharmacokinetic interactions were seen, additive effects on cognitive and…»
«Anticonceptivos orales, noretisterona y/o etinilestradiol: La administración de pregabalina junto con anticonceptivos orales como noretisterona y/o etinilestradiol, no influye en la farmacocinética…»
«Estudios in vivo y análisis farmacocinético de la población: En consecuencia, en los estudios in vivo , no se observaron interacciones farmacocinéticas relevantes desde el punto de vista clínico…»
«Estudios in vivo y análisis farmacocinético de la población: En consecuencia, en los estudios in vivo , no se observaron interacciones farmacocinéticas relevantes desde el punto de vista clínico…»
«Estudios in vivo y análisis farmacocinético de la población: En consecuencia, en los estudios in vivo , no se observaron interacciones farmacocinéticas relevantes desde el punto de vista clínico…»
«Estudios in vivo y análisis farmacocinético de la población: En consecuencia, en los estudios in vivo , no se observaron interacciones farmacocinéticas relevantes desde el punto de vista clínico…»
«DRUG INTERACTIONS: Since pregabalin is predominantly excreted unchanged in the urine, undergoes negligible metabolism in humans (less than 2% of a dose recovered in urine as metabolites), and does…»
«Estudios in vivo y análisis farmacocinético de la población: En consecuencia, en los estudios in vivo , no se observaron interacciones farmacocinéticas relevantes desde el punto de vista clínico…»
«DRUG INTERACTIONS: Multiple oral doses of pregabalin were co-administered with oxycodone, lorazepam, or ethanol. Although no pharmacokinetic interactions were seen, additive effects on cognitive and…»
«Anticonceptivos orales, noretisterona y/o etinilestradiol: La administración de pregabalina junto con anticonceptivos orales como noretisterona y/o etinilestradiol, no influye en la farmacocinética…»
«Estudios in vivo y análisis farmacocinético de la población: En consecuencia, en los estudios in vivo , no se observaron interacciones farmacocinéticas relevantes desde el punto de vista clínico…»
«DRUG INTERACTIONS: Since pregabalin is predominantly excreted unchanged in the urine, undergoes negligible metabolism in humans (less than 2% of a dose recovered in urine as metabolites), and does…»
«Estudios in vivo y análisis farmacocinético de la población: En consecuencia, en los estudios in vivo , no se observaron interacciones farmacocinéticas relevantes desde el punto de vista clínico…»
«DRUG INTERACTIONS: Since pregabalin is predominantly excreted unchanged in the urine, undergoes negligible metabolism in humans (less than 2% of a dose recovered in urine as metabolites), and does…»
«Estudios in vivo y análisis farmacocinético de la población: En consecuencia, en los estudios in vivo , no se observaron interacciones farmacocinéticas relevantes desde el punto de vista clínico…»
«DRUG INTERACTIONS: Since pregabalin is predominantly excreted unchanged in the urine, undergoes negligible metabolism in humans (less than 2% of a dose recovered in urine as metabolites), and does…»
«Estudios in vivo y análisis farmacocinético de la población: En consecuencia, en los estudios in vivo , no se observaron interacciones farmacocinéticas relevantes desde el punto de vista clínico…»
«DRUG INTERACTIONS: Since pregabalin is predominantly excreted unchanged in the urine, undergoes negligible metabolism in humans (less than 2% of a dose recovered in urine as metabolites), and does…»
«El empleo concomitante de Fentanilo Matrix Normon con otros depresores del sistema nervioso central (incluidos benzodiazepinas y otros sedantes/hipnóticos, opioides, anestésicos generales…»
«La administración concomitante de Petidina Basi con gabapentinoides (gabapentina y pregabalina) puede provocar depresión respiratoria, hipotensión, sedación profunda, coma o la muerte (véase la…»
«Medicamentos sedantes como las benzodiacepinas o medicamentos relacionados: El uso concomitante de opioides con medicamentos sedantes como las benzodiacepinas o medicamentos relacionados incrementa…»
«- la morfina debe utilizarse con precaución en pacientes que estén recibiendo simultáneamente otros depresores del sistema nervioso central, incluidos sedantes o hipnóticos, anestésicos generales…»
«El uso concomitante de tramadol con gabapentinoides (gabapentina y pregabalina) puede provocar depresión respiratoria, hipotensión, sedación profunda, coma o muerte.»
«El uso concomitante de opioides y gabapentinoides (gabapentina y pregabalina) aumenta el riesgo de sobredosis de opioides, depresión respiratoria y muerte.»
«El uso concomitante de opioides y gabapentinoides (gabapentina y pregabalina) aumenta el riesgo de sobredosis de opioides, depresión respiratoria y muerte.»
Pregabalin is evaluated for the following indications with varying evidence strength: Neuropathic pain (evidence tier A), Fibromyalgia (evidence tier B), Generalized anxiety disorder (evidence tier B). See the full indication matrix with dosing and citations above on this page.
What are the side effects of Pregabalin?+
Common side effects of Pregabalin (≥ 1 in 100): Sedation, drowsiness, Dizziness, Weight gain (5–10 kg over 6 months), Peripheral edema, Dry mouth, Euphoria (some patients welcome it, increasing abuse risk). See the Safety section for uncommon and serious reactions.
Is Pregabalin safe during pregnancy?+
AEMPS summary of product characteristics (section 4.6): animal studies have shown reproductive toxicity; pregabalin crosses the placenta in rats and may cross the human placenta. In a Nordic observational study of more than 2,700 women exposed in the first trimester, major congenital malformations were more common than in unexposed pregnancies (5.9% versus 4.1%; adjusted prevalence ratio 1.14, 95% CI 0.96 to 1.35) and than after exposure to lamotrigine (1.29) or duloxetine (1.39). Analyses of specific malformations showed a higher risk of nervous system, eye, orofacial cleft, urinary and genital malformations, but numbers were small and the estimates imprecise. Pregabalin should not be used in pregnancy unless clearly necessary, that is, when the benefit to the mother clearly outweighs the potential risk to the fetus.
Is Pregabalin compatible with breastfeeding?+
Transfers into breast milk. Manufacturer label advises against breastfeeding. Per LactMed, use when necessary with infant monitoring for sedation and poor weight gain.
Who should not take Pregabalin?+
Pregabalin is contraindicated in: Hypersensitivity; Age under 18 (for most indications except pediatric epilepsy from age 4); Rare hereditary galactose intolerance. Full list in the Safety section.
Lyrica is a harmless anti-stress drug+
pregabalin is a controlled substance with dependence and abuse risk. Use without a clinical diagnosis is unsafe.
Lyrica helps me sleep+
pregabalin causes sedation, but as a side effect — not as an indication. For insomnia, drugs with better safety profiles exist (melatonin, short-course doxylamine, third-generation hypnotics on indication). Self-medicating insomnia with pregabalin is unjustified.
Official sources
Direct links to regulator labels. Open in a new tab.